Robert Stuppy, MD
Cardiovascular Disease · Rogers, ARNPI 1316995137
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.5% of the total across 275 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 18.6% — the pattern of someone who eats at a lot of different presentations.
Across 275 payments — averaging $18.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$931
- Abbott$684
- Pfizer$642
- Novo Nordisk$344
- Medtronic$313
- Merck$283
- plus $2K from 18 others
What the payments were for
- Food & beverage$4,93098%
- Education$772%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 79 | $931 |
| Abbott | 24 | $684 |
| Pfizer | 43 | $642 |
| Novo Nordisk | 6 | $344 |
| Medtronic(2 entities) | 20 | $313 |
| Merck | 18 | $283 |
| Boston Scientific | 20 | $278 |
| Esperion Therapeutics, Inc. | 5 | $275 |
| Novartis | 15 | $225 |
| Abiomed | 1 | $141 |
| E.r. Squibb & Sons, L.L.C. | 9 | $137 |
| Baxter Healthcare | 5 | $104 |
| Alnylam Pharmaceuticals Inc. | 1 | $102 |
| Boehringer Ingelheim | 5 | $85 |
| Kiniksa Pharmaceuticals, Ltd. | 4 | $81 |
| Johnson & Johnson | 4 | $68 |
| Heartflow, Inc. | 1 | $64 |
| AstraZeneca | 4 | $63 |
| Sanofi-aventis U.S. LLC | 3 | $47 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $42 |
| Bayer | 2 | $34 |
| Atricure, Inc. | 1 | $31 |
| Amarin Pharma, Inc. | 1 | $18 |
| Regeneron Healthcare Solutions, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,007 in reported general payments places this provider in the 60th percentile of 130 cardiovascular disease providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 609 | $656,773 |
| JardianceEmpagliflozin | 278 | $269,086 |
| EntrestoSacubitril/Valsartan | 236 | $258,975 |
| XareltoRivaroxaban | 249 | $251,796 |
| CamzyosMavacamten | 22 | $171,954 |
| Repatha SureclickEvolocumab | 279 | $171,167 |
| FarxigaDapagliflozin Propanediol | 84 | $88,244 |
| Praluent PenAlirocumab | 56 | $38,959 |
| WegovySemaglutide | 14 | $18,905 |
| MultaqDronedarone Hcl | 17 | $17,659 |
| CorlanorIvabradine Hcl | 11 | $13,279 |
| Ezetimibe | 613 | $12,715 |
| Repatha SyringeEvolocumab | 18 | $9,596 |
| Metoprolol Succinate | 664 | $9,553 |
| Nebivolol Hcl | 179 | $9,211 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $642 | $656,773609 claims |
| Boehringer IngelheimJardiance | $85 | $269,086278 claims |
| NovartisEntresto | $225 | $258,975236 claims |
| Johnson & JohnsonXarelto | $68 | $251,796249 claims |
| E.r. Squibb & Sons, L.L.C.Camzyos | $137 | $171,95422 claims |
| AstraZenecaFarxiga | $63 | $88,24484 claims |
| Novo NordiskWegovy | $344 | $18,90514 claims |
| Sanofi-aventis U.S. LLCMultaq | $47 | $17,65917 claims |
| AmgenCorlanor | $931 | $13,27911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 130 cardiovascular disease providers in Arkansas.
Other cardiovascular disease in Rogers
- Amr El-ShafeiRogers$23K
- Kiran KurichetyRogers$9K
- Philip RileyRogers$8K
- Lance WeathersRogers$8K
- Larry WeathersRogers$6K
- Ian CawichLittle Rock$294K
- Barry TedderJonesboro$130K
- Harvinder DodEl Dorado$126K
- William RollefsonLittle Rock$74K
- Andre PaixaoLittle Rock$73K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.